Status:
COMPLETED
Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)
Lead Sponsor:
German CLL Study Group
Collaborating Sponsors:
University of Cologne
MedacSchering Onkologie
Conditions:
B-cell Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study aims to assess the short term efficacy of a combination immunochemotherapy in patients with relapsed B-cell chronic lymphatic leukemia.
Eligibility Criteria
Inclusion
- B-CLL in need of treatment
- One or two prior prior therapies
- WHO performance status 0-2
Exclusion
- Serum creatinine \> 1.5 ULN
- Major organ dysfunctions
- Pregnant or nursing
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00147901
Start Date
January 1 2005
End Date
November 1 2011
Last Update
October 3 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Cologne
Cologne, North Rhine-Westphalia, Germany, 50924